Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1...

Full description

Saved in:
Bibliographic Details
Main Authors: Amparo L. Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
mRNA vaccine
mRNA-1273
booster dose
immunogenicity
vaccine effectiveness
adolescents
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2436714
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2436714

Similar Items